COVID-19 research: an opinion piece.
Identifieur interne : 001397 ( Main/Corpus ); précédent : 001396; suivant : 001398COVID-19 research: an opinion piece.
Auteurs : L. Waters ; J K RockstrohSource :
- HIV medicine [ 1468-1293 ] ; 2020.
English descriptors
- KwdEn :
- Anti-Retroviral Agents (therapeutic use), Betacoronavirus (drug effects), COVID-19 (MeSH), Coronavirus Infections (drug therapy), Coronavirus Infections (prevention & control), Drug Combinations (MeSH), Drug Repositioning (standards), Drug Repositioning (trends), Humans (MeSH), Hydroxychloroquine (therapeutic use), Lopinavir (therapeutic use), Pandemics (prevention & control), Pneumonia, Viral (drug therapy), Pneumonia, Viral (prevention & control), Research (standards), Research (trends), Ritonavir (therapeutic use), SARS-CoV-2 (MeSH), Tenofovir (therapeutic use), Time Factors (MeSH).
- MESH :
- chemical , therapeutic use : Anti-Retroviral Agents, Hydroxychloroquine, Lopinavir, Ritonavir, Tenofovir.
- drug effects : Betacoronavirus.
- drug therapy : Coronavirus Infections, Pneumonia, Viral.
- prevention & control : Coronavirus Infections, Pandemics, Pneumonia, Viral.
- standards : Drug Repositioning, Research.
- trends : Drug Repositioning, Research.
- COVID-19, Drug Combinations, Humans, SARS-CoV-2, Time Factors.
Abstract
The unprecedented global scale of COVID-19 globally has triggered a race to discover interventions to reduce associated morbidity and mortality and rapid release of research findings prior to any degree of critical review. As with previous novel infection outbreaks, antiretrovirals are just one drug class that has been held up as a potential strategy for prophylaxis and treatment with scant evidence and risk of harm. Here we summarize the evidence for antiretrovirals to treat COVID-19 and, as a drug that has also been studied in HIV, hydroxychloroquine, and flag some of the pitfalls of using therapies that have not been evaluated robustly.
DOI: 10.1111/hiv.12913
PubMed: 32544304
PubMed Central: PMC7323295
Links to Exploration step
pubmed:32544304Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">COVID-19 research: an opinion piece.</title><author><name sortKey="Waters, L" sort="Waters, L" uniqKey="Waters L" first="L" last="Waters">L. Waters</name><affiliation><nlm:affiliation>Department of HIV & Sexual Health, Mortimer Market Centre, Central & North West London NHS Trust, London, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Rockstroh, J K" sort="Rockstroh, J K" uniqKey="Rockstroh J" first="J K" last="Rockstroh">J K Rockstroh</name><affiliation><nlm:affiliation>Department of Medicine I, Universitätsklinikum Bonn, Bonn, Germany.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32544304</idno><idno type="pmid">32544304</idno><idno type="doi">10.1111/hiv.12913</idno><idno type="pmc">PMC7323295</idno><idno type="wicri:Area/Main/Corpus">001397</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001397</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">COVID-19 research: an opinion piece.</title><author><name sortKey="Waters, L" sort="Waters, L" uniqKey="Waters L" first="L" last="Waters">L. Waters</name><affiliation><nlm:affiliation>Department of HIV & Sexual Health, Mortimer Market Centre, Central & North West London NHS Trust, London, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Rockstroh, J K" sort="Rockstroh, J K" uniqKey="Rockstroh J" first="J K" last="Rockstroh">J K Rockstroh</name><affiliation><nlm:affiliation>Department of Medicine I, Universitätsklinikum Bonn, Bonn, Germany.</nlm:affiliation></affiliation></author></analytic><series><title level="j">HIV medicine</title><idno type="eISSN">1468-1293</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Anti-Retroviral Agents (therapeutic use)</term><term>Betacoronavirus (drug effects)</term><term>COVID-19 (MeSH)</term><term>Coronavirus Infections (drug therapy)</term><term>Coronavirus Infections (prevention & control)</term><term>Drug Combinations (MeSH)</term><term>Drug Repositioning (standards)</term><term>Drug Repositioning (trends)</term><term>Humans (MeSH)</term><term>Hydroxychloroquine (therapeutic use)</term><term>Lopinavir (therapeutic use)</term><term>Pandemics (prevention & control)</term><term>Pneumonia, Viral (drug therapy)</term><term>Pneumonia, Viral (prevention & control)</term><term>Research (standards)</term><term>Research (trends)</term><term>Ritonavir (therapeutic use)</term><term>SARS-CoV-2 (MeSH)</term><term>Tenofovir (therapeutic use)</term><term>Time Factors (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-Retroviral Agents</term><term>Hydroxychloroquine</term><term>Lopinavir</term><term>Ritonavir</term><term>Tenofovir</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Betacoronavirus</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Coronavirus Infections</term><term>Pandemics</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="standards" xml:lang="en"><term>Drug Repositioning</term><term>Research</term></keywords><keywords scheme="MESH" qualifier="trends" xml:lang="en"><term>Drug Repositioning</term><term>Research</term></keywords><keywords scheme="MESH" xml:lang="en"><term>COVID-19</term><term>Drug Combinations</term><term>Humans</term><term>SARS-CoV-2</term><term>Time Factors</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The unprecedented global scale of COVID-19 globally has triggered a race to discover interventions to reduce associated morbidity and mortality and rapid release of research findings prior to any degree of critical review. As with previous novel infection outbreaks, antiretrovirals are just one drug class that has been held up as a potential strategy for prophylaxis and treatment with scant evidence and risk of harm. Here we summarize the evidence for antiretrovirals to treat COVID-19 and, as a drug that has also been studied in HIV, hydroxychloroquine, and flag some of the pitfalls of using therapies that have not been evaluated robustly.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32544304</PMID><DateCompleted><Year>2020</Year><Month>08</Month><Day>21</Day></DateCompleted><DateRevised><Year>2020</Year><Month>12</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1468-1293</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>8</Issue><PubDate><Year>2020</Year><Month>09</Month></PubDate></JournalIssue><Title>HIV medicine</Title><ISOAbbreviation>HIV Med</ISOAbbreviation></Journal><ArticleTitle>COVID-19 research: an opinion piece.</ArticleTitle><Pagination><MedlinePgn>536-540</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/hiv.12913</ELocationID><Abstract><AbstractText>The unprecedented global scale of COVID-19 globally has triggered a race to discover interventions to reduce associated morbidity and mortality and rapid release of research findings prior to any degree of critical review. As with previous novel infection outbreaks, antiretrovirals are just one drug class that has been held up as a potential strategy for prophylaxis and treatment with scant evidence and risk of harm. Here we summarize the evidence for antiretrovirals to treat COVID-19 and, as a drug that has also been studied in HIV, hydroxychloroquine, and flag some of the pitfalls of using therapies that have not been evaluated robustly.</AbstractText><CopyrightInformation>© 2020 British HIV Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Waters</LastName><ForeName>L</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-1379-1775</Identifier><AffiliationInfo><Affiliation>Department of HIV & Sexual Health, Mortimer Market Centre, Central & North West London NHS Trust, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rockstroh</LastName><ForeName>J K</ForeName><Initials>JK</Initials><Identifier Source="ORCID">0000-0003-2858-3888</Identifier><AffiliationInfo><Affiliation>Department of Medicine I, Universitätsklinikum Bonn, Bonn, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>07</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>HIV Med</MedlineTA><NlmUniqueID>100897392</NlmUniqueID><ISSNLinking>1464-2662</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D044966">Anti-Retroviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C558899">lopinavir-ritonavir drug combination</NameOfSubstance></Chemical><Chemical><RegistryNumber>2494G1JF75</RegistryNumber><NameOfSubstance UI="D061466">Lopinavir</NameOfSubstance></Chemical><Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber><NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance></Chemical><Chemical><RegistryNumber>99YXE507IL</RegistryNumber><NameOfSubstance UI="D000068698">Tenofovir</NameOfSubstance></Chemical><Chemical><RegistryNumber>O3J8G9O825</RegistryNumber><NameOfSubstance UI="D019438">Ritonavir</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D044966" MajorTopicYN="N">Anti-Retroviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004338" MajorTopicYN="N">Drug Combinations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058492" MajorTopicYN="Y">Drug Repositioning</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061466" MajorTopicYN="N">Lopinavir</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012106" MajorTopicYN="N">Research</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019438" MajorTopicYN="N">Ritonavir</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000068698" MajorTopicYN="N">Tenofovir</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">COVID</Keyword><Keyword MajorTopicYN="Y">COVID-19</Keyword><Keyword MajorTopicYN="Y">HIV</Keyword><Keyword MajorTopicYN="Y">antiretroviral</Keyword><Keyword MajorTopicYN="Y">hydroxychloroquine</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>05</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>06</Month><Day>09</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>06</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>6</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>8</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>6</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32544304</ArticleId><ArticleId IdType="doi">10.1111/hiv.12913</ArticleId><ArticleId IdType="pmc">PMC7323295</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>https://www.ecdc.europa.eu/en/geographical-distribution-2019-ncov-cases accessed 5th June 2020.</Citation></Reference><Reference><Citation>Rojek A, Horby P, Dunning J. Insights from clinical research completed during the west Africa Ebola virus disease epidemic. Lancet Infect Dis 2017; 17: e280-e292.</Citation></Reference><Reference><Citation>Farha MA, Brown ED. Drug repurposing for antimicrobial discovery. Nat Microbiol 2019; 4: 565-577.</Citation></Reference><Reference><Citation>ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 Feb 29. Identifier NCT04334928, Randomized Clinical Trial for the Prevention of SARS-CoV-2 Infection (COVID-19) in Healthcare Personnel (EPICOS); 2020 Apr 6 [cited 2020 Jun 12]; Available from: https://clinicaltrials.gov/ct2/show/NCT04334928.</Citation></Reference><Reference><Citation>ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 Feb 29. Identifier NCT04303299, Various Combination of Protease Inhibitors, Oseltamivir, Favipiravir, and Hydroxychloroquine for Treatment of COVID-19: A Randomized Control Trial (THDMS-COVID-19); 2020 Mar 11 [cited 2020 Jun12]; Available from: https://clinicaltrials.gov/ct2/show/NCT04303299.</Citation></Reference><Reference><Citation>ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 Feb 29. Identifier NCT04252274, Efficacy and Safety of Darunavir and Cobicistat for Treatment of COVID-19 (DC-COVID-19); 2020 Feb 5 [cited 2020 Jun 12]; Available from: https://clinicaltrials.gov/ct2/show/NCT04252274.</Citation></Reference><Reference><Citation>https://www.biorxiv.org/ accessed 10th May 2020.</Citation></Reference><Reference><Citation>https://www.medrxiv.org/ accessed 10th May 2020.</Citation></Reference><Reference><Citation>Ford N, Vitoria M, Rangaraj A, Norris SL, Calmy A, Doherty M. Systematic review of the efficacy and safety of antiretroviral drugs against SARS, MERS or COVID-19: initial assessment. J Int AIDS Soc 2020; 23: e25489. https://doi.org/10.1002/jia2.25489.</Citation></Reference><Reference><Citation>Li Y, Xie Z, Lin W, Cai W, Wen C, Guan Yet al.An exploratory randomized, controlled study on the efficacy and safety of lopinavir/ritonavir or arbidol treating adult patients hospitalized with mild/moderate COVID-19 (ELACOI). medRxiv preprint.</Citation></Reference><Reference><Citation>Cao B, Wang Y, Wen D et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med 2020; 382: 1787-1799. https://doi.org/10.1056/NEJMoa2001282.</Citation></Reference><Reference><Citation>Choy KT, Wong AY, Kaewpreedee P et al. Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro. Antiviral Res 2020; 3: 104786.</Citation></Reference><Reference><Citation>Cattaneo D. Does lopinavir really inhibit SARS-CoV-2? Pharmacol Res 2020; 158: 104898.</Citation></Reference><Reference><Citation>Baldelli S, Corbellino M, Clementi E, Cattaneo D, Gervasoni C. Lopinavir/ritonavir in COVID-19 patients: maybe yes, but at what dose? J AntimicrobChemother 2020 May 14 : dkaa190. https://doi.org/10.1093/jac/dkaa190.</Citation></Reference><Reference><Citation>https://www.jnj.com/lack-of-evidence-to-support-darunavir-based-hiv-treatments-for-coronavirus accessed 26th April 2020.</Citation></Reference><Reference><Citation>https://www.covid19-druginteractions.org/ accessed 12thJune 2020.</Citation></Reference><Reference><Citation>https://www.biorxiv.org/content/ 10.1101/2020.04.04.020925v1.full.pdf.</Citation></Reference><Reference><Citation>Richardson S, Hirsch JS, Narasimhan M et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA 2020: e206775.323(20):2052-2059.</Citation></Reference><Reference><Citation>Elfiky Abdo A. Ribavirin, remdesivir, sofosbuvir, galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study. Life Sci 2020; 253: 117592.</Citation></Reference><Reference><Citation>Ramírez D, Caballero J. Is it reliable to use common molecular docking methods for comparing the binding affinities of enantiomer pairs for their protein target? Int J Mol Sci 2016; 17: 525.</Citation></Reference><Reference><Citation>Melchjorsen J, Risør MW, Søgaard OS et al. Tenofovir selectively regulates production of inflammatory cytokines and shifts the IL-12/IL-10 balance in human primary cells. J Acquir Immune DeficSyndr 2011; 57: 265-275.</Citation></Reference><Reference><Citation>Härter G, Spinner CD, Roider J et al. COVID-19 in people living with human immunodeficiency virus: a case series of 33 patients. Infection 2020;11: 1-6. https://doi.org/10.1007/s15010-020-01438-z</Citation></Reference><Reference><Citation>Gervasoni C, Meraviglia P, Riva A et al. Clinical features and outcomes of HIV patients with coronavirus disease 2019. Clin Infect Dis. 2020 May 14. pii: ciaa579. https://doi.org/10.1093/cid/ciaa579</Citation></Reference><Reference><Citation>Del Amo J, Polo R, Moerno S et al. Incidence and severity of COVID-19 in HIV-positive persons resceiving antiretroviral therapy: a cohort study (published online ahead, of print, 2020 Jun 26. Ann Intern Med. 2020;10.7326/M20-3689. https://doi.org/10.7326/M20-3689</Citation></Reference><Reference><Citation>Savarino A, Shytaj IL. Chloroquine and beyond: exploring anti-rheumatic drugs to reduce immune hyperactivation in HIV/AIDS. Retrovirology 2015; 12: 51.</Citation></Reference><Reference><Citation>Paton NI, Goodall RL, Dunn DT et al. Hydroxychloroquine Trial Team: effects of hydroxychloroquine on immune activation and disease progression among HIV-infected patients not receiving antiretroviral therapy: a randomized controlled trial. JAMA 2012; 308: 353-361.</Citation></Reference><Reference><Citation>Owens B. Excitement around hydroxychloroquine for treating COVID-19 causes challenges for rheumatology. Lancet Rheumatol 2020; 2: e257.</Citation></Reference><Reference><Citation>De Lamballerie X, Boisson V, Reynier JC et al. On chikungunya acute infection and chloroquine treatment. Vector Borne Zoonotic Dis 2008; 8: 837-9.</Citation></Reference><Reference><Citation>Gautret P, Lagier JC, Parola P et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 2020; 105949.</Citation></Reference><Reference><Citation>https://app.sermo.com/covid19-barometer?utm_campaign=wwwsermo_covid19 accessed 11th May 2020.</Citation></Reference><Reference><Citation>Decree No. 2020-314 of March 25, 2020 supplementing Decree No. 2020-293 of March 23, 2020 prescribing the general measures necessary to deal with the Covid-19 epidemic in the context of the state of health emergency. Accessed at https://beta.legifrance.gouv.fr/jorf/id/JORFTEXT000041755775 12th May 2020.</Citation></Reference><Reference><Citation>BMJ Best Practice: https://bestpractice.bmj.com/topics/en-gb/3000168/emergingtxs#referencePop408 accessed 12th May 2020.</Citation></Reference><Reference><Citation>Borba MGS, Val FFA, Sampaio VS et al. Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical Trial. JAMA Netw Open 2020; 3: e208857.</Citation></Reference><Reference><Citation>https://www.fda.gov/drugs/drug-safety-and-availability/fda-cautions-against-use-hydroxychloroquine-or-chloroquine-covid-19-outside-hospital-setting-or accessed 11th May 2020.</Citation></Reference><Reference><Citation>Nguyen LS, Dolladille C, Drici MD et al. Cardiovascular Toxicities Associated With Hydroxychloroquine and Azithromycin: An Analysis of the World Health Organization Pharmacovigilance Database. Circulation 2020 doi: 10.1161/CIRCULATIONAHA.120.048238. Online ahead of print.</Citation></Reference><Reference><Citation>Yazdany J, Kim AHJ. Use of Hydroxychloroquine and Chloroquine During the COVID-19 Pandemic: What Every Clinician Should Know. Ann Intern Med 2020; 172: 754-755. https://jamanetwork.com/channels/health-forum/fullarticle/2764607 accessed 11th May 2020</Citation></Reference><Reference><Citation>Geleris J, Sun Y, Platt J et al. Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19. N Engl J Med 2020. https://doi.org/10.1056/NEJMoa2012410</Citation></Reference><Reference><Citation>Magagnoli J, Narendran S, Pereira Fet al. Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19. doi: 10.1101/2020.04.16.20065920 accessed 11th May 2020.</Citation></Reference><Reference><Citation>Million M, Lagier JC, Gautret Pet al. Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France. doi: 10.1016/j.tmaid.2020.101738 accessed 11th May 2020.</Citation></Reference><Reference><Citation>Mehra MR, Desai SS, Ruschitzka F, Patel AN. Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet 2020; S0140-6736: 31180-6.</Citation></Reference><Reference><Citation>Mehra MR, Ruschitzka F, Patel AN. Retraction-Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet 2020; 395: P1820.</Citation></Reference><Reference><Citation>https://www.recoverytrial.net/; accessed 30th June 2020.</Citation></Reference><Reference><Citation>https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments; accessed 9th June 2020.</Citation></Reference><Reference><Citation>https://clinicaltrials.gov/ct2/show/NCT04315948 accessed 09/06/2020.</Citation></Reference><Reference><Citation>Boulware DR, Pullen MF, Bangdiwala AS et al. A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. N Engl J Med. 2020. https://doi.org/10.1056/NEJMoa2016638</Citation></Reference><Reference><Citation>Cohen M. Hydroxychloroquine for the prevention of Covid-19 - searching for evidence. N Engl J Med. 2020. https://doi.org/10.1056/NEJMe2020388</Citation></Reference><Reference><Citation>Bruce R, Chauvin A, Trinquart L, Ravaud P, Boutron I. Impact of interventions to improve the quality of peer review of biomedical journals: a systematic review and meta-analysis. BMC Med. 2016; 14(1):85.</Citation></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001397 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 001397 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidChloroV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= pubmed:32544304
|texte= COVID-19 research: an opinion piece.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:32544304" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a CovidChloroV1
| This area was generated with Dilib version V0.6.38. |  |